Zobrazeno 1 - 10
of 2 992
pro vyhledávání: '"Levie K"'
Autor:
Yulyaningsih E; Denali Therapeutics, South San Francisco, United States., Suh JH; Denali Therapeutics, South San Francisco, United States., Fanok M; Denali Therapeutics, South San Francisco, United States., Chau R; Denali Therapeutics, South San Francisco, United States., Solanoy H; Denali Therapeutics, South San Francisco, United States., Takahashi R; Denali Therapeutics, South San Francisco, United States., Bakardjiev AI; Denali Therapeutics, South San Francisco, United States., Becerra I; Denali Therapeutics, South San Francisco, United States., Benitez NB; Denali Therapeutics, South San Francisco, United States., Chiu CL; Denali Therapeutics, South San Francisco, United States., Davis SS; Denali Therapeutics, South San Francisco, United States., Dowdle WE; Denali Therapeutics, South San Francisco, United States., Earr T; Denali Therapeutics, South San Francisco, United States., Estrada AA; Denali Therapeutics, South San Francisco, United States., Gill A; Denali Therapeutics, South San Francisco, United States., Ha C; Denali Therapeutics, South San Francisco, United States., Haddick PCG; Denali Therapeutics, South San Francisco, United States., Henne KR; Denali Therapeutics, South San Francisco, United States., Larhammar M; Denali Therapeutics, South San Francisco, United States., Leung AW; Denali Therapeutics, South San Francisco, United States., Maciuca R; Denali Therapeutics, South San Francisco, United States., Memarzadeh B; Denali Therapeutics, South San Francisco, United States., Nguyen HN; Denali Therapeutics, South San Francisco, United States., Nugent AA; Denali Therapeutics, South San Francisco, United States., Osipov M; Denali Therapeutics, South San Francisco, United States., Ran Y; Denali Therapeutics, South San Francisco, United States., Rebadulla K; Denali Therapeutics, South San Francisco, United States., Roche E; Denali Therapeutics, South San Francisco, United States., Sandmann T; Denali Therapeutics, South San Francisco, United States., Wang J; Denali Therapeutics, South San Francisco, United States., Lewcock JW; Denali Therapeutics, South San Francisco, United States., Scearce-Levie K; Denali Therapeutics, South San Francisco, United States., Kane LA; Denali Therapeutics, South San Francisco, United States., Sanchez PE; Denali Therapeutics, South San Francisco, United States.
Publikováno v:
ELife [Elife] 2024 Sep 17; Vol. 12. Date of Electronic Publication: 2024 Sep 17.
Autor:
Hernandez A; Syapse, Inc., West Chester, Pennsylvania., Sweeney V; Syapse, Inc., West Chester, Pennsylvania., Deitsch A; Syapse, Inc., West Chester, Pennsylvania., Levie K; Syapse, Inc., West Chester, Pennsylvania., Boice L; Syapse, Inc., West Chester, Pennsylvania., Lloyd K; Syapse, Inc., West Chester, Pennsylvania., Martin J; Syapse, Inc., West Chester, Pennsylvania., Wicks M; Syapse, Inc., West Chester, Pennsylvania., Widmer L; Syapse, Inc., West Chester, Pennsylvania.
Publikováno v:
Journal of registry management [J Registry Manag] 2024 Summer; Vol. 51 (2), pp. 81-86.
Autor:
Craig RA 2nd; Denali Therapeutics Inc., South San Francisco, California 94080, United States., De Vicente J; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Estrada AA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Feng JA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Lexa KW; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Canet MJ; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Dowdle WE; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Erickson RI; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Flores BN; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Haddick PCG; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Kane LA; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Lewcock JW; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Moerke NJ; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Poda SB; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Sweeney Z; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Takahashi RH; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Tong V; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Wang J; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Yulyaningsih E; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Solanoy H; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Sanchez PE; Denali Therapeutics Inc., South San Francisco, California 94080, United States., Tang L; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Xu M; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Zhang R; Department of Chemistry, WuXi AppTec Co., Ltd., Tianjin 300457, China., Osipov M; Denali Therapeutics Inc., South San Francisco, California 94080, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Apr 11; Vol. 67 (7), pp. 5758-5782. Date of Electronic Publication: 2024 Mar 21.
Autor:
Hsiao-Nakamoto J; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; These authors contributed equally., Chiu CL; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; These authors contributed equally., VandeVrede L; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA., Ravi R; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Vandenberg B; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; Present address: Brittany Vandenberg, Washington State University, Pullman, WA 99164, USA., De Groot J; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; Present address: Jack DeGroot: Prime Medicine Inc., Cambridge, MA 02139, USA., Tsogtbaatar B; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Fang M; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Auger P; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; Present address: Paul Auger: Nurix Therapeutics, San Francisco, CA 94158, USA., Gould NS; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Marchioni F; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Powers CA; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; Present address: Casey A. Powers: Stanford University, Stanford, CA 94305, USA., Davis SS; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Suh JH; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Alkabsh J; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Heuer HW; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA., Lago AL; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA., Scearce-Levie K; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; Present address: Kimberly Scearce-Levie: Cajal Neuroscience, Seattle, WA 98109, USA., Seeley WW; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA., Boeve BF; Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA., Rosen HJ; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA., Berger A; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Tsai R; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Di Paolo G; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA., Boxer AL; Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, 94158, USA.; These authors contributed equally., Bhalla A; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; These authors contributed equally., Huang F; Denali Therapeutics Inc., 161 Oyster Point, South San Francisco, CA, 94080, USA.; These authors contributed equally.
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2024 Feb 12. Date of Electronic Publication: 2024 Feb 12.
Autor:
Vissers, M.F.J.M., Heuberger, J.A.A.C., Groeneveld, G.J., Nijhuis, J.O., Deyn, P.P. de, Hadi, S., Harris, J., Tsai, R.M., Cruz-Herranz, A., Huang, F., Tong, V., Erickson, R., Zhu, Y.D., Scearce-Levie, K., Hsiao-Nakamoto, J., Tang, X.Y., Chang, M., Fox, B.M., Pomponio, R.J., Alonso-Alonso, M., Zilberstein, M., Atassi, N., Troyer, M.D., Ho, C.
Publikováno v:
Clinical and translational science, 15(8), 2010-2023. Wiley
Clinical and Translational Science, 15(8), 2010-2023. WILEY
Clinical and translational science
Clinical and Translational Science, 15(8), 2010-2023. WILEY
Clinical and translational science
RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to protect ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::af01500ec9f2208e7f2c9d74b053cf6c
https://research.rug.nl/en/publications/68746f94-9889-48a0-8f8d-428a9c348bbf
https://research.rug.nl/en/publications/68746f94-9889-48a0-8f8d-428a9c348bbf
Autor:
Levie K; Syapse, San Francisco, California., Cromartie B; Syapse, San Francisco, California., Wicks M; Syapse, San Francisco, California., Burkhart J; Syapse, San Francisco, California., Kennedy S; Syapse, San Francisco, California., Hess D; Syapse, San Francisco, California., Wolf F; Syapse, San Francisco, California., Widmer L; Syapse, San Francisco, California.
Publikováno v:
Journal of registry management [J Registry Manag] 2023 Summer; Vol. 50 (2), pp. 60-63.
Autor:
Jennings D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Huntwork-Rodriguez S; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Vissers MFJM; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands., Daryani VM; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Diaz D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Goo MS; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Chen JJ; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Maciuca R; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Fraser K; Biogen Inc, Cambridge, Massachusetts, USA., Mabrouk OS; Biogen Inc, Cambridge, Massachusetts, USA., van de Wetering de Rooij J; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.; PRA Health Sciences, Groningen, the Netherlands., Heuberger JAAC; Centre for Human Drug Research, Leiden, the Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands., Borin MT; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Cruz-Herranz A; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Graham D; Biogen Inc, Cambridge, Massachusetts, USA., Scearce-Levie K; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., De Vicente J; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Henry AG; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Chin P; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Ho C; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA., Troyer MD; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2023 Mar; Vol. 38 (3), pp. 386-398. Date of Electronic Publication: 2023 Feb 18.
Autor:
van Lengerich B; Denali Therapeutics, Inc., South San Francisco, CA, USA., Zhan L; Denali Therapeutics, Inc., South San Francisco, CA, USA., Xia D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Chan D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Joy D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Park JI; Denali Therapeutics, Inc., South San Francisco, CA, USA., Tatarakis D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Calvert M; Denali Therapeutics, Inc., South San Francisco, CA, USA., Hummel S; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Lianoglou S; Denali Therapeutics, Inc., South San Francisco, CA, USA., Pizzo ME; Denali Therapeutics, Inc., South San Francisco, CA, USA., Prorok R; Denali Therapeutics, Inc., South San Francisco, CA, USA., Thomsen E; Denali Therapeutics, Inc., South San Francisco, CA, USA., Bartos LM; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Beumers P; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Capell A; Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany., Davis SS; Denali Therapeutics, Inc., South San Francisco, CA, USA., de Weerd L; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Dugas JC; Denali Therapeutics, Inc., South San Francisco, CA, USA., Duque J; Denali Therapeutics, Inc., South San Francisco, CA, USA., Earr T; Denali Therapeutics, Inc., South San Francisco, CA, USA., Gadkar K; Denali Therapeutics, Inc., South San Francisco, CA, USA., Giese T; Denali Therapeutics, Inc., South San Francisco, CA, USA., Gill A; Denali Therapeutics, Inc., South San Francisco, CA, USA., Gnörich J; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Ha C; Denali Therapeutics, Inc., South San Francisco, CA, USA., Kannuswamy M; Denali Therapeutics, Inc., South San Francisco, CA, USA., Kim DJ; Denali Therapeutics, Inc., South San Francisco, CA, USA., Kunte ST; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Kunze LH; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Lac D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Lechtenberg K; Denali Therapeutics, Inc., South San Francisco, CA, USA., Leung AW; Denali Therapeutics, Inc., South San Francisco, CA, USA., Liang CC; Denali Therapeutics, Inc., South San Francisco, CA, USA., Lopez I; Denali Therapeutics, Inc., South San Francisco, CA, USA., McQuade P; Takeda Pharmaceutical Company, Cambridge, MA, USA., Modi A; Denali Therapeutics, Inc., South San Francisco, CA, USA., Torres VO; Denali Therapeutics, Inc., South San Francisco, CA, USA., Nguyen HN; Denali Therapeutics, Inc., South San Francisco, CA, USA., Pesämaa I; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany., Propson N; Denali Therapeutics, Inc., South San Francisco, CA, USA., Reich M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Graduate School of Systemic Neurosciences, Ludwig Maximilians University Munich, Planegg-Martinsried, Germany., Robles-Colmenares Y; Denali Therapeutics, Inc., South San Francisco, CA, USA., Schlepckow K; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Slemann L; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Solanoy H; Denali Therapeutics, Inc., South San Francisco, CA, USA., Suh JH; Denali Therapeutics, Inc., South San Francisco, CA, USA., Thorne RG; Denali Therapeutics, Inc., South San Francisco, CA, USA., Vieira C; Denali Therapeutics, Inc., South San Francisco, CA, USA., Wind-Mark K; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany., Xiong K; Denali Therapeutics, Inc., South San Francisco, CA, USA., Zuchero YJY; Denali Therapeutics, Inc., South San Francisco, CA, USA., Diaz D; Denali Therapeutics, Inc., South San Francisco, CA, USA., Dennis MS; Denali Therapeutics, Inc., South San Francisco, CA, USA., Huang F; Denali Therapeutics, Inc., South San Francisco, CA, USA., Scearce-Levie K; Denali Therapeutics, Inc., South San Francisco, CA, USA., Watts RJ; Denali Therapeutics, Inc., South San Francisco, CA, USA., Haass C; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Lewcock JW; Denali Therapeutics, Inc., South San Francisco, CA, USA., Di Paolo G; Denali Therapeutics, Inc., South San Francisco, CA, USA., Brendel M; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Sanchez PE; Denali Therapeutics, Inc., South San Francisco, CA, USA. sanchez@dnli.com., Monroe KM; Denali Therapeutics, Inc., South San Francisco, CA, USA. monroe@dnli.com.
Publikováno v:
Nature neuroscience [Nat Neurosci] 2023 Mar; Vol. 26 (3), pp. 416-429. Date of Electronic Publication: 2023 Jan 12.
Publikováno v:
In Value in Health June 2023 26(6) Supplement:S379-S379
Autor:
Craig RA 2nd; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Fox BM; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Hu C; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Lexa KW; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Osipov M; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Thottumkara AP; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Larhammar M; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Miyamoto T; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Rana A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Kane LA; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Yulyaningsih E; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Solanoy H; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Nguyen H; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Chau R; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Earr T; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Kajiwara Y; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Fleck D; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Lucas A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Haddick PCG; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Takahashi RH; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Tong V; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Wang J; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Canet MJ; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Poda SB; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Scearce-Levie K; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Srivastava A; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Sweeney ZK; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States., Xu M; Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China., Zhang R; Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China., He J; Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China., Lei Y; Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China., Zhuo Z; Department of Chemistry, WuXi AppTec Co., Ltd., 168 Nanhai Road, 10th Avenue, Tianjin TEDA, Tianjin 300457, China., de Vicente J; Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16290-16312. Date of Electronic Publication: 2022 Dec 05.